Trials / Completed
CompletedNCT06586580
Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1
Le Traitement Par Lenvatinib + Anti-PD1 Du Mélanome Métastatique
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 18 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis is that treatment with Lenvatinib + Pembrolizumab is less effective in real life than in clinical trials. In fact, an objective response rate \< 20% and a worse tolerability of the treatment in real life with ≥50% of severe toxicities are expected.
Conditions
Timeline
- Start date
- 2023-03-30
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2024-09-19
- Last updated
- 2024-09-19
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06586580. Inclusion in this directory is not an endorsement.